Comparison of activity level among patients with chronic liver disease

Disability and Rehabilitation

Volumn 35, Issue 11, 2013, Pages 907-912

  Price, Jillian Kallman ^a,b,c,d   Srivastava, Ragini ^a,b   Bai, Chunhong ^a,b   Diao, Guoqing ^e   Gerber, Lynn H ^b,c,d   Younossi, Zobair M ^a,b,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Beatty Liver and Obesity Research Center   (United States)

^d GEORGE MASON UNIVERSITY   (United States)

^e George Mason University   (United States)

Author keywords

Activity level; Hepatitis; Human activity profile; Liver; Nonalcoholic fatty liver disease

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CHRONIC DISEASE; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; DISABILITY; EXERCISE; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE; REGRESSION ANALYSIS; RISK FACTOR; SELF REPORT; SEX RATIO;

ACTIVITIES OF DAILY LIVING; ADULT; AGE DISTRIBUTION; AGED; BODY MASS INDEX; CHRONIC DISEASE; DISABILITY EVALUATION; EXERCISE; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; QUESTIONNAIRES; REGRESSION ANALYSIS; RISK FACTORS; SELF REPORT; SEX DISTRIBUTION;

EID: 84877124250     PISSN: 09638288     EISSN: 14645165     Source Type: Journal    
DOI: 10.3109/09638288.2012.712601     Document Type: Article

References (48)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: fndings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
3. Alameri HF, Sanai FM, Al Dukhayil M, Azzam NA, Al-Swat KA, Hersi AS, Abdo AA. Six Minute Walk Test to assess functional capacity in chronic liver disease patients. World J Gastroenterol 2007;13:3996-4001.
4. Church TS, Kuk JL, Ross R, Priest EL, Biltof E, Biltof E, Blair SN. Association of cardiorespiratory ftness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 2006;130:2023-2030.
5. Krasnof JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related ftness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008;47:1158-1166.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-1231.
7. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-240.
8. Krasnof JB, Painter PL, Merriman RB, Bass N, Wallace J P. Health-related ftness and physical activity participation among individuals with nonalcoholic fatty liver disease. Med. Sci. Sports Exerc. 2007;39:S445.
9. McMillan KP, Kuk JL, Church TS, Blair SN, Ross R. Independent associations between liver fat, visceral adipose tissue, and metabolic risk factors in men. Appl Physiol Nutr Metab 2007;32:265-272.
10. Bondini S, Kallman J, Wheeler A, Prakash S, Gramlich T, Jondle DM, Younossi ZM. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int 2007;27:607-611.
11. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-644.
12. Yousnossi, ZM. Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. J Gastroenterol Hepatol 2004;19:S253-S257.
13. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-265.
14. Bondini S, Younossi ZM. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol 2006;52:135-143.
15. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
16. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
17. Younossi ZM, Diehl AM, Ong J P. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35:746-752.
18. Lonardo A, Loria P, Adinolf LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006;13:73-80.
19. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006;55:123-130.
20. Takuma Y, Nouso K, Makino Y, Saito S, Takayama H, Takahara M, Takahashi H, et al. Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma. Liver Int 2007;27:620-626.
21. Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol 2007;41:513-517.
22. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
23. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008;47:1856-1862.
24. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN. Cardiorespiratory ftness attenuates metabolic-associated mortality risk in normal weight, overweight, and obese men. Med Sci Sports Exerc 2004;36:S135.
25. Perseghin G, Ntali G, De Cobelli F, Lattuada G, Esposito A, Belloni E, Canu T, et al. Abnormal lef ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance. Diabetes Care 2007;30:1520-1526.
26. Warburton DE, Nicol C W, Bredin SS. Health benefts of physical activity: the evidence. CMAJ 2006;174:801-809.
27. Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB. Relationship of exercise to quality of life in cancer patients beginning chemotherapy. J Pain Symptom Manage 2011;41:859-869.
28. Fitzgerald GK, Piva SR, Gil AB, Wisniewski SR, Oddis C V, Irrgang JJ. Agility and perturbation training techniques in exercise therapy for reducing pain and improving function in people with knee osteoarthri-tis: a randomized clinical trial. Phys Ter 2011;91:452-469.
29. Archer T, Fredriksson A, Schütz E, Kostrzewa RM. Infuence of physical exercise on neuroimmunological functioning and health: aging and stress. Neurotox Res 2011;20:69-83.
30. Gulve EA. Exercise and glycemic control in diabetes: benefts, challenges, and adjustments to pharmacotherapy. Phys Ter 2008;88: 1297-1321.
31. Basta M, Lin HM, Pejovic S, Sarrigiannidis A, Bixler E, Vgontzas AN. Lack of regular exercise, depression, and degree of apnea are predictors of excessive daytime sleepiness in patients with sleep apnea: sex difer-ences. J Clin Sleep Med 2008;4:19-25.
32. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79.
33. Rafq N, Stepanova M, Lam B, Younossi ZM. Type 2 diabetes, obesity and hypertension are associated with mortality in hepatitis C patients. [abstract] J Hepatol 2009;50:S57.
34. Stepanova M, Rafq N, Mir HM, Bornman IM, Younossi ZM. Mortality and liver related mortality in patients with chronic liver disease: association with components of metabolic syndrome (MS). [abstract] Gastroenterology 2009;136:A-803.
35. Younossi Z, Matteoni CA, Gramlich TL, Boparai N, Price L, McCullough AJ. Diabetes and non-alcoholic fatty liver disease: a worrisome combination. Gastroenterology 1999;116:1292.
36. Fitzgibbon ML, Stolley MR, Kirschenbaum DS. Obese people who seek treatment have diferent characteristics than those who do not seek treatment. Health Psychol 1993;12:342-345.
37. Hankinson AL, Daviglus ML, Bouchard C, Carnethon M, Lewis CE, Schreiner PJ, Liu K, Sidney S. Maintaining a high physical activity level over 20 years and weight gain. JAMA 2010;304:2603-2610.
38. Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S, Gerber L, Younossi ZM. Health-related quality of life in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ter 2007;26:815-820.
39. Afendy A, Kallman JB, Stepanova M, Younoszai Z, Aquino RD, Bianchi G, Marchesini G, Younossi ZM. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ter 2009;30:469-476.
40. Daughton DM, Fix AJ. Human activity profle: professional manual. Odessa, FL, USA: Psychological Assessment Resources Inc; 1988.
41. WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;157-163.
42. Kallman JB, Tran S, Arsalla A, Haddad D, Stepanova M, Fang Y, Wrobel VJ et al. Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat 2011;18:70-76.
43. Soni M, Awad M, Earley ME, Kallman JB, Younossi ZM. Longitudinal study of dietary habits and activity level in patients with chronic liver disease (CLD). [abstract] Gastroenterology 2011;140(Suppl.) :S-617.
44. Kim CH, Kallman JB, Bai C, Pawloski L, Gewa C, Arsalla A, Sabatella ME, Younossi ZM. Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg 2010;20:154-160.
45. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 2011;17:3377-3389.
46. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. [abstract] Hepatology 2008;48:1791-1798.
47. Kallman J, Winter PM, Moon J, Earley M, Gerber L, Younossi Z. Determination of relationships between objective and self-reports of fatigue and physical performance in subjects with chronic liver disease. Hepatology 2010;52:1243A.
48. Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopa-thy-a double-blind placebo-controlled study. Aliment Pharmacol Ter 2011;34:853-861.